Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
Sabeena SharmaRahul Deshmukh

Abstract

Parkinson's disease (PD) is a neurological disorder characterized by tremors, rigidity and bradykinesia. PD is caused by selective degeneration of the dopaminergic neurons, which originate in the substantia nigra pars compacta (SNc) and project into the striatum. Levodopa is the most effective drug, used in the treatment of PD. However, the long-term use of levodopa produce complications which are highly disabling fluctuations and dyskinesias and representing one of the major challenge to the existing drug therapy of PD. Recent studies has indicated that the pulsatile stimulation of striatal postsynaptic receptors led to sensitization of dopaminergic receptors which leads to levodopa induced dyskinesias. In spite of the extensive research in this field, the pathogenesis of levodopa induced dyskinesia is still unclear. In recent years animal models of PD has provided important information to understand the effect of specific receptors and post-receptor molecular mechanisms underlying the development of dyskinetic movements. The present review is aimed to discuss the neurobiological mechanisms of levodopa induced dyskinesia and the therapeutic strategies to overcome this problem.

References

Sep 1, 1990·The Journal of Comparative Neurology·B Lavoie, A Parent
Mar 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·M HerkenhamK C Rice
Dec 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·W S YoungM R Brann
Oct 2, 1970·Science·K Y NgI J Kopin
Mar 18, 1997·Proceedings of the National Academy of Sciences of the United States of America·D K Giang, B F Cravatt
Aug 1, 1997·Trends in Biochemical Sciences·S M LohmannH R De Jonge
Oct 29, 2000·Trends in Neurosciences·A ParentM Parent
Oct 29, 2000·Trends in Neurosciences·T N Chase, J D Oh
Mar 29, 2001·Neuroscience·A LopezJ L Labandeira-Garcia
Jun 16, 2001·European Journal of Pharmacology·V Di MarzoJ J Fernandez-Ruiz
Jun 30, 2001·Trends in Pharmacological Sciences·V Di MarzoL De Petrocellis
Aug 3, 2001·Nature Reviews. Neuroscience·E BezardC E Gross
Nov 3, 2001·Science·P Greengard
May 31, 2002·Pharmacological Reviews·A C HowlettR G Pertwee
Jun 28, 2002·Physiological Reviews·U Benjamin Kaupp, Reinhard Seifert
Mar 6, 2003·CNS Drugs·J Ludovic Croxford
Apr 1, 2003·Nature Neuroscience·Barbara PicconiPaolo Calabresi
Sep 25, 2003·Biochemical Society Transactions·D M F Cooper
Oct 1, 2003·British Journal of Pharmacology·Ruth A Ross
Feb 21, 2004·Nature Reviews. Neuroscience·Gareth M Thomas, Richard L Huganir
Apr 7, 2004·Genes to Cells : Devoted to Molecular & Cellular Mechanisms·Noriko OshiroKazuyoshi Yonezawa
Aug 13, 2004·The European Journal of Neuroscience·Giuseppe SancesarioGiorgio Bernardi
Nov 9, 2005·Nature Reviews. Neuroscience·P Jeffrey ConnFerdinando Nicoletti

❮ Previous
Next ❯

Citations

Jan 29, 2016·Movement Disorders : Official Journal of the Movement Disorder Society·Angelo AntoniniJanet A Benesh
Oct 11, 2015·Neuropharmacology·Yanwei LiChristian Hölscher
Sep 27, 2015·European Journal of Pharmacology·YiMei ChenChristian Hölscher
Apr 20, 2016·Drugs·Dhanya Vijayakumar, Joseph Jankovic
Jan 27, 2017·International Journal of Molecular Sciences·Cristoforo ComiMarco Cosentino
Jan 30, 2018·Frontiers in Neurology·Wen-Wen WangCheng-Long Xie
Nov 10, 2018·Expert Opinion on Pharmacotherapy·Nataša Dragašević-MiškovićVladimir S Kostić
May 1, 2020·Annals of Clinical and Translational Neurology·Yayun YanYing Chang
Sep 15, 2020·Experimental Neurobiology·Joshua A BlosserDaewoo Lee
May 19, 2017·Frontiers in Aging Neuroscience·Jing-Ya LinZhen-Guo Liu
Dec 10, 2019·Annals of Clinical and Translational Neurology·Shi-Ying FanFan-Gang Meng
Aug 29, 2021·Pharmaceuticals·E Maruthi Prasad, Shih-Ya Hung

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Basal ganglia in Parkinson's disease (MDS)

The basal ganglia is comprised of the neostriatum, the external and internal pallidal segments, the subthalamic nucleus, the substantia nigra pars reticulata, and the pars compacta of the substantia nigra. The basal ganglia circuitry is responsible for the correct execution of voluntary movements and is implicated in Parkinson's disease. Here is the latest research investigating the basal ganglia in Parkinson's disease.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Related Papers

Current Drug Targets. CNS and Neurological Disorders
S M CardosoC R Oliveira
La Revue de médecine interne
V Fraix
IDrugs : the Investigational Drugs Journal
Timothy BrownJonathan Brotchie
© 2021 Meta ULC. All rights reserved